SEC Form 4 · accession 0001553878-16-000060
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akshay Vaishnaw
Officer — EVP, R&D, CMO
Period of report
Nov 30, 2016
Accepted (ET)
Dec 2, 2016 · 4:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 30, 2016 | M | 29,165 | $22.75 | A | 34,915 | D | |
| Common StockF2 | Nov 30, 2016 | S | 14,368 | $44.3435 | D | 20,547 | D | |
| Common StockF3 | Nov 30, 2016 | S | 13,297 | $45.5488 | D | 7,250 | D | |
| Common StockF4 | Nov 30, 2016 | S | 1,500 | $46.1387 | D | 5,750 | D | |
| Common StockF5 | holding | — | — | — | 223 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6,F1 | $22.75 | Nov 30, 2016 | M | 29,165 | D | — | Dec 14, 2016 | Common Stock | 29,165 | 0 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 17, 2016. The 29,165 options exercised and sold by the reporting person were due to expire on December 14, 2016.
- F2Sale prices ranged from $43.90 to $44.86.
- F3Sale prices ranged from $44.98 to $45.95.
- F4Sale prices ranged from $45.98 to $46.80.
- F5The reporting person owns 223 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F6The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.